Turkish Neurosurgery
Can dynamic susceptibility contrast perfusion imaging be utilized to detect isocitrate dehydrogenase gene mutation in gliomas?
Abidin Kılınçer1, Hakan Cebeci1, Nusret Seher1, Mehmet Sedat Durmaz1, Emine Uysal1, Mert Şahinoğlu2, Ender Köktekir2, Hakan Karabağlı2, Pınar Karabağlı3, Yahya Paksoy1
1Selçuk University, Radiology, Konya,
2Selçuk University, Neurosurgery, Konya,
3Selçuk University, Pathology, Konya,
DOI: 10.5137/1019-5149.JTN.36166-21.4

Aim:Dynamic susceptibility contrast perfusion imaging (DSC-PI) is a frequently utilized advanced imaging technique in brain tumors. We explored the ability of DSC-PI to detect isocitrate dehydrogenase (IDH) gene mutation in gliomas.Material and Methods:Preoperative DSC-PI data on histopathologically proven gliomas obtained between January 2015 and December 2019 were reviewed retrospectively. All magnetic resonance imaging (MRI) examinations were performed using a 1.5-T scanner. The maximum relative cerebral blood volume (rCBVmax), percentage signal recovery (PSR), and normalized PSR of tumor cores were calculated. Differences in these values between IDH-mutant and wild-type gliomas were compared, and receiver operating characteristic curves were generated.Results:The patients (32 females, 47 males) were aged 21–76 years (mean 50.7 ± 15 years). The rCBVmax and all PSR values differed significantly between patients with IDH-mutant and those with wild-type tumors (P < 0.01 for all comparisons). Conclusion:The rCBVmax and PSR values obtained by DSC-PI may facilitate noninvasive detection of the IDH mutation status of gliomas. PSR provided more reliable values for differentiation of IDH-mutant gliomas from wild-type gliomas.

Corresponding author : Abidin Kılınçer